STOCK TITAN

InMode Ltd. Ordinary Shares - INMD STOCK NEWS

Welcome to our dedicated page for InMode Ltd. Ordinary Shares news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on InMode Ltd. Ordinary Shares stock.

InMode Ltd. (NASDAQ: INMD) is a leading global provider of innovative medical technologies specializing in minimally and non-invasive surgical aesthetic and medical treatment solutions. The company's product portfolio spans three major energy-based treatment categories: face & body contouring, medical aesthetics, and women's health. Their products, such as BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, are widely utilized in plastic surgery, dermatology, gynecology, and ophthalmology.

InMode’s flagship products, including Fractora for skin texture improvement, Lumecca for photorejuvenation, Diolaze for hair removal, and BodyFX for body contouring, are designed to deliver effective and exciting aesthetic solutions.

InMode has consistently invested in research and development to expand its intellectual property portfolio, which is pivotal for maintaining its competitive edge. Recently, the company initiated legal action against BTL Industries for patent infringement regarding their radio-frequency based feminine rejuvenation products.

Despite market headwinds, including higher interest rates affecting equipment financing and slower purchase decisions, InMode has shown resilience with a 2% increase in Q3 2023 revenues, totaling $123.1 million. The company also saw a 13% rise in international sales during this period.

In Q1 2024, InMode announced pre-orders for two new platforms, IgniteRF and Optimus Max, which are anticipated to drive future growth. Additionally, a new share repurchase program and the appointment of Dr. Michael Anghel as Chairman of the Board underscore the company’s commitment to shareholder value.

InMode's innovative spirit is further highlighted by their recent partnership with P1 Offshore Racing, sponsoring the only female driver, Victoria Rand, signaling a strong commitment to empowering women.

For more detailed information and the latest updates, visit InMode's official website.

Rhea-AI Summary

InMode Ltd. (Nasdaq: INMD) announced participation in three virtual investor conferences. CEO Moshe Mizrahy and CFO Yair Malca will present at the Stifel 2021 Healthcare Conference on November 16 at 9:20 PM EST, the Hidden Gem Conference on November 17 at 11:15 AM EST, and the Canaccord Virtual MedTech Forum on November 18 at 1:30 PM EST. Webcasts will be available for the Stifel and Canaccord events. Investors can schedule one-on-one virtual meetings during these conferences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
conferences
-
Rhea-AI Summary

InMode Ltd. (Nasdaq: INMD) reported record revenues of $94.2 million for Q3 2021, a 58% increase from Q3 2020. The company's GAAP net income reached $44.7 million, resulting in a GAAP diluted EPS of $0.52, up from $0.28 a year prior. Non-GAAP net income was $47.9 million, with an EPS of $0.55. The company has a total cash position of $387.4 million as of September 30, 2021. Looking ahead, InMode projects 2021 revenues between $343 million and $347 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary

InMode Ltd. (NASDAQ: INMD) announced expectations for record revenue for Q3 2021, projecting between $93.5M and $94M. The company also anticipates Non-GAAP earnings per diluted share to be in the range of $0.53 to $0.54, reflecting a 2-for-1 stock split effective September 30, 2021. Full-year revenue guidance has been raised to $343M - $347M with a Non-GAAP gross margin of 84% - 86%. A conference call to discuss results will take place on October 26, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.62%
Tags
none
Rhea-AI Summary

InMode Ltd. (Nasdaq: INMD) has announced a two-for-one (2:1) share split, effective September 30, 2021, with a record date of September 27, 2021. Every share held by shareholders on the record date will automatically convert into two shares, impacting all shareholders uniformly without affecting their ownership percentage. The share split was approved by the board of directors on September 14, 2021. This move aims to enhance the liquidity of the shares and make them more accessible to investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
Rhea-AI Summary

InMode Ltd. (Nasdaq: INMD), a leader in innovative medical technologies, will participate in two upcoming virtual conferences. On September 14, CEO Moshe Mizrahy and CFO Yair Malca will present at the Baird Global Healthcare Conference at 4:20 PM ET. Additionally, they will participate in the Citi Small-Mid Cap Growth Conference on September 17, with opportunities for one-on-one meetings. Access to the conference webcasts can be found here.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
conferences
-
Rhea-AI Summary

InMode Ltd. (Nasdaq: INMD) has launched the EvolveX platform featuring Transform technology, designed for hands-free, non-invasive body transformation with zero downtime. The platform meets rising post-lockdown demand for non-surgical treatments, offering a unique all-in-one solution that remodels skin, treats fat, and sculpts muscles. EvolveX’s innovative features allow physicians to customize treatments addressing specific patient needs, promising consistent results. CEO Moshe Mizrahy emphasized the growing demand for such solutions, backed by InMode's strong R&D pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
Rhea-AI Summary

InMode Ltd. (Nasdaq: INMD) has launched the EmpowerRF Women's Wellness platform, designed to deliver advanced feminine wellness therapies. This multi-functional solution utilizes various complementary technologies to address a range of conditions such as pain relief, blood circulation, and urinary incontinence. CEO Moshe Mizrahy emphasized the company's commitment to addressing unmet needs in women's wellness, while North American President Shakil Lakhani highlighted InMode's ongoing investment in this market despite competitors withdrawing. The platform aims to improve women's quality of life through minimally invasive procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
none
-
Rhea-AI Summary

InMode Ltd. (Nasdaq: INMD), a leader in medical technologies, announced its participation in key upcoming conferences. On August 12, Yair Malca, CFO, will engage in a virtual fireside chat at Canaccord Genuity's Growth Virtual Conference, while Moshe Mizrahy, CEO, joins him for a similar event at UBS Genomics 2.0 in Laguna Beach. Additionally, both executives will be available for one-on-one meetings at the Needham Virtual Med Tech Conference on August 16. For more details, visit InMode's events page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences
-
Rhea-AI Summary

InMode Ltd. (Nasdaq: INMD) reported a remarkable 184% increase in second-quarter 2021 revenues, reaching $87.3 million, driven primarily by its proprietary surgical technologies. GAAP net income surged to $40.9 million, up from $8.6 million in Q2 2020, with diluted EPS rising to $0.95. The company boasts a strong cash position of $332.9 million. Management's outlook for 2021 anticipates revenues between $305 million and $315 million, with non-GAAP EPS projected between $3.10 and $3.25. InMode is also launching a new platform, Empower, focused on women's health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
Rhea-AI Summary

InMode Ltd. (Nasdaq: INMD) has announced expectations for its second-quarter 2021 financial results, to be released on July 28, 2021. Preliminary estimates indicate record revenue between $86.5 million and $87.0 million, and Non-GAAP earnings per diluted share in the range of $1.00 to $1.01. The company has also increased its full-year 2021 revenue guidance to between $305 million and $315 million, with a projected non-GAAP gross margin of 84% to 86%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.54%
Tags
none

FAQ

What is the current stock price of InMode Ltd. Ordinary Shares (INMD)?

The current stock price of InMode Ltd. Ordinary Shares (INMD) is $17.08 as of December 20, 2024.

What is the market cap of InMode Ltd. Ordinary Shares (INMD)?

The market cap of InMode Ltd. Ordinary Shares (INMD) is approximately 1.3B.

What products does InMode Ltd. offer?

InMode offers a range of innovative aesthetic solutions including BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8.

What are InMode's core business categories?

InMode's core business categories include face & body contouring, medical aesthetics, and women's health.

Which markets does InMode serve?

InMode serves markets including plastic surgery, dermatology, gynecology, and ophthalmology.

How did InMode perform in Q3 2023?

In Q3 2023, InMode reported revenues of $123.1 million, a 2% increase from the same period in 2022, and a 13% increase in international sales.

What are some of InMode's flagship products?

InMode's flagship products include Fractora, Lumecca, Diolaze, and BodyFX, offering solutions for skin texture improvement, photorejuvenation, hair removal, and body contouring.

What recent legal actions has InMode taken?

InMode filed a patent infringement complaint against BTL Industries concerning their radio-frequency based feminine rejuvenation products.

What new platforms has InMode recently announced?

InMode has announced pre-orders for two new platforms, IgniteRF and Optimus Max, expected to drive future growth.

Who is the new Chairman of InMode's Board?

Dr. Michael Anghel has been appointed as the new Chairman of InMode's Board, effective July 25, 2024.

What partnership has InMode recently entered into?

InMode partnered with P1 Offshore Racing and is sponsoring the only female driver, Victoria Rand, as part of Class 1.

Where can I find more information about InMode?

For more information and the latest updates, visit InMode's official website at https://inmodemd.com/.

InMode Ltd. Ordinary Shares

Nasdaq:INMD

INMD Rankings

INMD Stock Data

1.30B
68.05M
10.76%
64.22%
8.44%
Medical Devices
Healthcare
Link
United States of America
Yokne'am